Connect Biopharma (NASDAQ:CNTB – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Connect Biopharma to similar businesses based on the strength of its institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.
Risk and Volatility
Connect Biopharma has a beta of 0.06, indicating that its share price is 94% less volatile than the S&P 500. Comparatively, Connect Biopharma’s peers have a beta of -1.85, indicating that their average share price is 285% less volatile than the S&P 500.
Insider & Institutional Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 22.6% of Connect Biopharma shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Connect Biopharma | 1 | 0 | 8 | 0 | 2.78 |
| Connect Biopharma Competitors | 9915 | 15326 | 45725 | 1601 | 2.54 |
Connect Biopharma currently has a consensus price target of $5.88, indicating a potential upside of 783.19%. As a group, “Biotechnology” companies have a potential upside of 108.91%. Given Connect Biopharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Connect Biopharma is more favorable than its peers.
Earnings and Valuation
This table compares Connect Biopharma and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Connect Biopharma | $2.95 million | -$55.48 million | -0.58 |
| Connect Biopharma Competitors | $721.77 million | $9.60 million | -18.46 |
Connect Biopharma’s peers have higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Connect Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Connect Biopharma | N/A | -182.86% | -127.70% |
| Connect Biopharma Competitors | -12,516.26% | -215.91% | -31.70% |
Summary
Connect Biopharma beats its peers on 9 of the 13 factors compared.
About Connect Biopharma
Connect Biopharma is a biopharmaceutical company focused on developing treatments for inflammatory diseases, particularly conditions driven by T cells. The company has operated in the United States and China and has advanced its drug candidates through clinical development. Its lead candidate, rademikibart (formerly CBP-201), is an investigational antibody that targets the interleukin-4 receptor alpha pathway, which is involved in allergic inflammation. It has been studied for conditions including atopic dermatitis and asthma.
Receive News & Ratings for Connect Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Connect Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
